Trinity Biotech Q1 FY26 net loss narrows to $4.4 million; revenue rises 43% to $10.8 million
PUBT · 06/16 13:10
Share
Listen to the news
- Trinity Biotech Q1 2026 revenue rose 43% to $10.8 million.
- Gross margin climbed 10.2 percentage points to 35.4%.
- Net loss narrowed to $4.4 million; adjusted EBITDA improved to negative $1.1 million.
- Received purchase orders for over 2 million TrinScreen HIV tests, scheduled for Q3 2026 fulfillment.
- CEO John Gillard cited recent Ebola and Hantavirus outbreaks as highlighting ongoing infectious-disease public health risks.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trinity Biotech plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606160910PRIMZONEFULLFEED9747759) on June 16, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved